Occam Places CBO for Oncology Biotech Accent Therapeutics
In September 2018, Occam recruited David Brower as Chief Business Officer of Accent Therapeutics, a developer of biomarker-driven cancer medicines.
David has held a number of life science business development, strategy, and investing roles prior to joining Accent. Most recently, he led the business development function for Blueprint Medicines, where he completed various strategic transactions, including its seminal partnerships with Roche Pharmaceuticals, CStone Pharmaceuticals, and Alexion Pharmaceuticals. Prior to Blueprint Medicines, David was a member of Pfizer Pharmaceuticals’ Worldwide Business Development team, focusing on licensing and M&A transactions and business development strategy. David began his career as a healthcare trader and investor for Lehman Brothers and Barclays Capital.
Recent Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.